242 related articles for article (PubMed ID: 9362440)
1. Clinical research update: zoledronate.
Body JJ
Cancer; 1997 Oct; 80(8 Suppl):1699-701. PubMed ID: 9362440
[TBL] [Abstract][Full Text] [Related]
2. A dose-finding study of zoledronate in hypercalcemic cancer patients.
Body JJ; Lortholary A; Romieu G; Vigneron AM; Ford J
J Bone Miner Res; 1999 Sep; 14(9):1557-61. PubMed ID: 10469284
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
4. Current and future directions in medical therapy: hypercalcemia.
Body JJ
Cancer; 2000 Jun; 88(12 Suppl):3054-8. PubMed ID: 10898351
[TBL] [Abstract][Full Text] [Related]
5. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
[TBL] [Abstract][Full Text] [Related]
6. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Body JJ; Bartl R; Burckhardt P; Delmas PD; Diel IJ; Fleisch H; Kanis JA; Kyle RA; Mundy GR; Paterson AH; Rubens RD
J Clin Oncol; 1998 Dec; 16(12):3890-9. PubMed ID: 9850035
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid: a new parenteral bisphosphonate.
Li EC; Davis LE
Clin Ther; 2003 Nov; 25(11):2669-708. PubMed ID: 14693298
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates and metastatic breast carcinoma.
Lipton A
Cancer; 2003 Feb; 97(3 Suppl):848-53. PubMed ID: 12548585
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Berenson JR; Rosen LS; Howell A; Porter L; Coleman RE; Morley W; Dreicer R; Kuross SA; Lipton A; Seaman JJ
Cancer; 2001 Apr; 91(7):1191-200. PubMed ID: 11283917
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
Major PP; Coleman RE
Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
[TBL] [Abstract][Full Text] [Related]
12. Treatment of tumor-induced osteolysis by APD.
Burckhardt P; ThiƩbaud D; Perey L; von Fliedner V
Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
[TBL] [Abstract][Full Text] [Related]
13. Advances in the biology and treatment of myeloma bone disease.
Berenson JR
Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S16-20. PubMed ID: 11757204
[TBL] [Abstract][Full Text] [Related]
14. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone.
Arden-Cordone M; Siris ES; Lyles KW; Knieriem A; Newton RA; Schaffer V; Zelenakas K
Calcif Tissue Int; 1997 May; 60(5):415-8. PubMed ID: 9115157
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.
Berenson JR
Semin Oncol; 2001 Apr; 28(2 Suppl 6):25-34. PubMed ID: 11346862
[TBL] [Abstract][Full Text] [Related]
16. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
[TBL] [Abstract][Full Text] [Related]
17. [Bisphosphonates and bone metastases].
Lortholary A; Jadaud E; Berthaud P
Bull Cancer; 1999 Sep; 86(9):732-8. PubMed ID: 10519966
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Gordon DH
Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid: a review of its use in patients with advanced cancer.
Perry CM; Figgitt DP
Drugs; 2004; 64(11):1197-211. PubMed ID: 15161327
[TBL] [Abstract][Full Text] [Related]
20. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
Berenson JR; Vescio R; Henick K; Nishikubo C; Rettig M; Swift RA; Conde F; Von Teichert JM
Cancer; 2001 Jan; 91(1):144-54. PubMed ID: 11148571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]